GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

Status Completed

Clinical Trial Summary

This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation.

Clinical Trial Description

This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation. GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03618667
Study type	Interventional
Source	Samsung Medical Center
Contact
Status	Completed
Phase	Phase 2
Start date	January 22, 2018
Completion date	April 28, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03291977` - Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)	Phase 3
Active, not recruiting	`NCT03665545` - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma	Phase 1/Phase 2
Terminated	`NCT03714334` - DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma	Phase 1
Recruiting	`NCT03277638` - Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)	Phase 1/Phase 2
Completed	`NCT03158389` - NCT Neuro Master Match - N²M² (NOA-20)	Phase 1/Phase 2
Completed	`NCT03522298` - Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma	Phase 2
Recruiting	`NCT03213002` - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM	Phase 1/Phase 2
Completed	`NCT03232424` - NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma	Phase 1
Active, not recruiting	`NCT04116658` - First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Phase 1/Phase 2
Recruiting	`NCT04128774` - Function and Composition of Regulatory B Cells in Participants With Glioblastoma
Completed	`NCT03744026` - Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9	Phase 1/Phase 2
Completed	`NCT04610229` - Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.	N/A
Active, not recruiting	`NCT02974738` - A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)	Phase 1
Recruiting	`NCT03025893` - A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme	Phase 2/Phase 3
Active, not recruiting	`NCT03181477` - Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas	N/A
Completed	`NCT03075514` - Ketogenic Diets as an Adjuvant Therapy in Glioblastoma	N/A